Hold Rating on Edwards Lifesciences Amid TAVR Challenges and Competitive Pressures
After Edwards Lifesciences (EW.US) unexpectedly lowered its TAVR expectations, both Morgan Stanley and Truist significantly reduced their target stock prices.
In the performance outlook section, the company expects the growth of transcatheter aortic valve replacement (TAVR) products in 2024 to be lower than previously announced expectations. Subsequently, the company's stock price suffered a heavy blow as pessimistic expectations led investors to sell off the stock.
Peijia Medical-B (09996.HK): Edwards Lifesciences plans to acquire JenaValve through a merger.
On July 26th, Guolong News reported that Peijia Medical-B (09996.HK) announced that its wholly-owned subsidiary, Marvel Finder Limited, holds about 1.91% (calculated on a fully diluted and conversion basis) of JenaValve's minority equity, which is recorded in the company's comprehensive financial statements as a financial asset measured at fair value. JenaValve has notified the company that on July 23, 2024 (US time), Edwards Lifesciences (through its wholly-owned subsidiary) agreed to acquire the shares.
Heard on the Street Recap: Detroit Blues -- WSJ
Edwards Lifesciences (NYSE:EW) Plunges 31% After J.P. Morgan and Truist Downgrades
Top 20 U.S. stock trading volume on July 25th: Ford dropped sharply by 18.4%, averaging a loss of 0.3 million per electric vehicle.
On Thursday, Nvidia, the top trading company in the US, fell by 1.72%, marking its third consecutive day of decline with a turnover of 51.53 billion US dollars. Nvidia's partner SMC is reportedly raising 0.95 billion US dollars to stimulate business development with the help of AI server trends. Tesla, ranked second, rose 1.97% with a turnover of 22.201 billion US dollars. UBS Group believes that the profit return of Tesla's AI project is still far away, but the market has given it overly high expectations for its development potential, leading to its stock price far above its reasonable valuation. The bank reaffirmed its "sell" rating on Tesla. Tesla CEO Musk said on Tuesday that Tesla's value lies mainly in its autonomous driving.
Corporate Earnings, GDP Data Leave Equity Markets Mixed
Nvidia, Alphabet, Microsoft, Drag S&P, Nasdaq Lower | Wall Street Today
Edwards Lifesciences Options Spot-On: On July 25th, 158.3K Contracts Were Traded, With 74,578 Open Interest
Edwards Lifesciences Stock Plummeted Today. Here's Why
US Equities Markets End Mixed Thursday as Markets Parse Economic Data, Quarterly Results
Edwards Lifesciences Cut to Hold From Buy by TD Cowen
Edwards Lifesciences Price Target Cut to $70.00/Share From $100.00 by TD Cowen
Top Midday Decliners
Gold Down 2.5%; Northrop Grumman Posts Upbeat Earnings
Why Edwards Lifesciences Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Sector Update: Health Care Stocks Mixed in Afternoon Trading
Industrials, Energy Push US Equity Indexes Higher Ahead of Fed's Preferred Inflation Print
These Analysts Slash Their Forecasts On Edwards Lifesciences Following Q2 Results
Edwards Lifesciences Shares Tumble After Downgrades, Price Target Cuts Following Q2 Results